Can I read Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data on EtoBox?

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data by Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia‐Manero; Alessandra Ferrajoli; Srdan Verstovsek; William Wierda; Michael Keating; Moshe Talpaz is a Medicine article available to read on EtoBox.

What is Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data about?

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown (to date) a survival advantage for imatinib. This was most likely because approximately 90% of patients receiving IFN‐α plus ara‐C changed to imatinib therapy after a median of 8 months into therapy. ## METHODS The authors analyzed the results with imatinib therapy in patients with newly diagnosed Ph‐positive CML in chronic phase and compared their outcome with patients who received IFN‐α regimens. A total of 187 patients with Ph‐positive CML in early chronic phase treated with imatinib were compared with a historic group of 650 similar patients treated with IFN‐α regimens from 1982 until 1997. ## RESULTS Patients who received imatinib were significantly older and had significantly more bone marrow basophilia and less leukocytosis. The complete cytogenetic response (Ph 0%) rates were better with imatinib (81% vs. 32%; __P__ < 0.001), as were the survival rates (30‐month estimated survival

Who reads Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data?

Author

Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia‐Manero; Alessandra Ferrajoli; Srdan Verstovsek; William Wierda; Michael Keating; Moshe Talpaz

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

2003

Language

EN

Field

Medicine (Health Sciences)